Total Payments
$256,530
2024 Payments
$12,014
Companies
19
Transactions
371
Medicare Patients
307
Medicare Billing
$25,017
Payment Breakdown by Category
Consulting$154,161 (60.1%)
Other$46,955 (18.3%)
Research$17,382 (6.8%)
Education$13,852 (5.4%)
Travel$13,155 (5.1%)
Food & Beverage$11,026 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $154,161 | 43 | 60.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,955 | 15 | 17.1% |
| Unspecified | $17,382 | 23 | 6.8% |
| Education | $13,852 | 50 | 5.4% |
| Travel and Lodging | $13,155 | 25 | 5.1% |
| Food and Beverage | $11,026 | 214 | 4.3% |
| Charitable Contribution | $3,000 | 1 | 1.2% |
Payments by Type
General
$239,148
348 transactions
Research
$17,382
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $87,915 | 82 | $0 (2024) |
| GENZYME CORPORATION | $57,333 | 71 | $0 (2024) |
| Genentech, Inc. | $30,424 | 15 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $16,532 | 55 | $0 (2024) |
| Biogen, Inc. | $13,028 | 45 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $12,170 | 19 | $0 (2024) |
| F. Hoffmann-La Roche AG | $10,836 | 11 | $0 (2024) |
| Genentech USA, Inc. | $9,390 | 11 | $0 (2024) |
| Celgene Corporation | $8,533 | 5 | $0 (2024) |
| AbbVie Inc. | $6,050 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,014 | 45 | F. Hoffmann-La Roche AG ($5,621) |
| 2023 | $45,944 | 71 | EMD Serono, Inc. ($25,898) |
| 2022 | $25,624 | 46 | EMD Serono, Inc. ($15,104) |
| 2021 | $17,568 | 20 | EMD Serono, Inc. ($10,138) |
| 2020 | $35,514 | 26 | EMD Serono, Inc. ($12,076) |
| 2019 | $58,496 | 79 | EMD Serono, Inc. ($21,974) |
| 2018 | $24,083 | 38 | GENZYME CORPORATION ($23,523) |
| 2017 | $37,287 | 46 | GENZYME CORPORATION ($28,525) |
All Payment Transactions
371 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $60.47 | General |
| 10/21/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,582.25 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,055.80 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $555.53 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 09/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Education | In-kind items and services | $11.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $74.25 | General |
| Category: Immunology | ||||||
| 09/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.59 | General |
| Category: Rare Disease | ||||||
| 08/29/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 07/29/2024 | Amgen Inc. | UPLIZNA (Biological) | Education | In-kind items and services | $11.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Education | In-kind items and services | $11.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/22/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Immunology | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $96.24 | General |
| Category: Neurology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $911.14 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $707.93 | Research |
| Study: One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $430.58 | Research |
| Study: Ocrelizumab treatment and risk for composite disability progression in non-Hispanic Black and Hispanic or Latino individuals by self-identity and genetic ancestry with relapsing multiple sclerosis: findings from the OPERA I and II trials • Category: Immunology | ||||||
| 06/17/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 05/21/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $106.00 | General |
| Category: Rare Disease | ||||||
| 05/20/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $32.78 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/20/2024 | Amgen Inc. | UPLIZNA (Biological) | Education | In-kind items and services | $10.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $118.15 | General |
| Category: Neurology | ||||||
| 05/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Rare Disease | ||||||
| 05/10/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $33.90 | General |
| Category: Immunology | ||||||
| 05/07/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 05/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $35.87 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,750 | 4 |
| COMB157G2301 | Novartis Pharmaceuticals Corporation | $2,169 | 1 |
| AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB | F. Hoffmann-La Roche AG | $1,828 | 2 |
| Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,611 | 2 |
| Ocrelizumab in Patients with RMS | F. Hoffmann-La Roche AG | $1,582 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $1,407 | 2 |
| One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,289 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,117 | 1 |
| Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the Open-Label, Single-Arm, Multicenter, Phase IV CHIMES Trial | F. Hoffmann-La Roche AG | $799.08 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Sclerosis Patients Who Participated in Gen | GENZYME CORPORATION | $730.91 | 1 |
| One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial | F. Hoffmann-La Roche AG | $707.93 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $678.00 | 3 |
| Ocrelizumab treatment and risk for composite disability progression in non-Hispanic Black and Hispanic or Latino individuals by self-identity and genetic ancestry with relapsing multiple sclerosis: findings from the OPERA I and II trials | F. Hoffmann-La Roche AG | $430.58 | 1 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $282.22 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 70 | 75 | $33,915 | $6,661 |
| 2022 | 2 | 68 | 76 | $32,290 | $6,175 |
| 2021 | 1 | 68 | 78 | $31,200 | $5,271 |
| 2020 | 4 | 101 | 109 | $41,879 | $6,911 |
Total Patients
307
Total Services
338
Medicare Billing
$25,017
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 46 | $18,400 | $3,435 | 18.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 29 | $15,515 | $3,226 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 62 | $24,800 | $4,425 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 14 | $7,490 | $1,749 | 23.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 68 | 78 | $31,200 | $5,271 | 16.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 41 | $16,400 | $2,702 | 16.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 36 | $19,260 | $2,209 | 11.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 15 | $3,941 | $1,029 | 26.1% |
| 99225 | Subsequent observation care, typically 25 minutes per day | Facility | 2020 | 17 | 17 | $2,278 | $970.84 | 42.6% |
About Dr. Lilyana Amezcua, M.D
Dr. Lilyana Amezcua, M.D is a Neurology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1306031240.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lilyana Amezcua, M.D has received a total of $256,530 in payments from pharmaceutical and medical device companies, with $12,014 received in 2024. These payments were reported across 371 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($154,161).
As a Medicare-enrolled provider, Amezcua has provided services to 307 Medicare beneficiaries, totaling 338 services with total Medicare billing of $25,017. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Los Angeles, CA
- Active Since 09/13/2007
- Last Updated 12/02/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1306031240
Products in Payments
- LEMTRADA (Drug) $27,730
- OCREVUS (Biological) $27,160
- Ocrevus (Biological) $23,303
- AUBAGIO (Drug) $22,888
- Soliris (Drug) $11,252
- Ozanimod (Drug) $8,150
- MAYZENT (Drug) $7,329
- KESIMPTA (Drug) $4,351
- DISEASE STATE (Drug) $3,353
- Evobrutinib $3,128
- ARZERRA (Drug) $2,750
- Mavenclad (Biological) $1,503
- GILENYA (Drug) $1,406
- BRIUMVI (Drug) $1,377
- TYSABRI (Biological) $437.16
- MAVENCLAD (Drug) $432.06
- UPLIZNA (Drug) $365.86
- SOLIRIS (Biological) $339.29
- VUMERITY (Drug) $326.27
- MS DISEASE STATE (Drug) $284.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Los Angeles
Dr. Andrew Blumenfeld, M.d, M.D
Neurology — Payments: $6.2M
Neurology $6.2M
Jeffrey Cummings, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Dr. Alan Rapoport, M.d, M.D
Neurology — Payments: $1.0M
Neurology $1.0M
Said Beydoun, M.d, M.D
Neurology — Payments: $967,384
Neurology $967,384
Mark Lew, M.d, M.D
Neurology — Payments: $735,848
Neurology $735,848
Dr. Dawn Eliashiv, M.d, M.D
Neurology — Payments: $465,988
Neurology $465,988